Realities of limited manufacturing capacity for COVID-19 vaccines hit Horizon’s Tepezza launch

In a blow to what has been one of the more successful drug launches of the year, Operation Warp Speed has commandeered some of Horizon’s manufacturing slots for thyroid eye disease drug Tepezza to prioritize a COVID-19 vaccine.

The decision marks one of the first of what could be more drug shortages for therapeutics that rely on contract manufacturing...